ストックスクリーナーアプリを入手
12.95
3.14%
-0.42
アフターアワーズ：
13.69
0.74
+5.71%
前日終値:
$13.37
開ける：
$13.6
24時間の取引高:
211.70K
Relative Volume:
0.95
時価総額：
$382.88M
収益：
$65.42M
当期純損益:
$-32.96M
株価収益率:
-10.20
EPS:
-1.27
ネットキャッシュフロー:
$-19.87M
1週間 パフォーマンス:
+10.78%
1か月 パフォーマンス:
+24.28%
6か月 パフォーマンス:
+41.53%
1年 パフォーマンス:
+52.00%
1日の値動き範囲:
$12.91
$13.61
1週間の範囲:
$11.56
$13.61
52週間の値動き範囲:
$5.45
$15.11
Neuropace Inc Stock (NPCE) Company Profile
NPCE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
12.95 | 382.88M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
129.05 | 231.50B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.95 | 154.04B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
387.53 | 144.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.11 | 105.58B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.50 | 43.95B | 5.54B | 4.18B | 623.10M | 7.00 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-21 | 開始されました | UBS | Buy |
| 2024-03-14 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 開始されました | Leerink Partners | Outperform |
| 2023-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-08-24 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 開始されました | Lake Street | Buy |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 開始されました | Robert W. Baird | Outperform |
| 2021-05-17 | 開始されました | JP Morgan | Overweight |
| 2021-05-17 | 開始されました | Morgan Stanley | Overweight |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Neuropace Inc (NPCE) 最新ニュース
Earnings call transcript: NeuroPace beats Q1 2025 EPS forecast, stock rises - Investing.com Australia
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq
NeuroPace Inc SEC 10-Q Report - TradingView
Neuropace Inc reports results for the quarter ended March 31Earnings Summary - TradingView
NeuroPace Q1 2025 presentation: revenue jumps 24%, expands epilepsy treatment market - Investing.com Australia
Neuropace, Inc. Q1 Revenue USD 22.524 Million Versus. IBES Estimate USD 21.8 Million - marketscreener.com
NeuroPace Inc.: Q1 Earnings Snapshot - NewsTimes
NeuroPace Reports First Quarter 2025 Financial Results - The Manila Times
NeuroPace (NPCE) to Release Earnings on Wednesday - Defense World
Recent Price Trend in NeuroPace (NPCE) is Your Friend, Here's Why - Yahoo Finance
NeuroPace, Inc. (NASDAQ:NPCE) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable - simplywall.st
NeuroPace, Inc. (NASDAQ:NPCE) Shares Acquired by Wells Fargo & Company MN - Defense World
NeuroPace (NPCE) to Release Quarterly Earnings on Wednesday - MarketBeat
Barclays PLC Acquires 6,976 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
JPMorgan Chase & Co. Purchases 52,829 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
Nantahala Capital Management LLC Sells 45,817 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
Study: NeuroPace’s Technology Can Help Reduce Epileptic Seizures - Medical Product Outsourcing
28,547 Shares in NeuroPace, Inc. (NASDAQ:NPCE) Purchased by Walleye Capital LLC - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Shares Acquired by JPMorgan Chase & Co. - Defense World
Retail investors who hold 34% of NeuroPace, Inc. (NASDAQ:NPCE) gained 10%, institutions profited as well - simplywall.st
Geode Capital Management LLC Has $3.62 Million Stock Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Short Interest in NeuroPace, Inc. (NASDAQ:NPCE) Rises By 45.8% - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Sees Significant Growth in Short Interest - Defense World
NeuroPace Inc (NPCE) Trading Down 3.19% on Apr 15 - GuruFocus
NeuroPace expects minimal tariff impact, maintains guidance By Investing.com - Investing.com South Africa
NeuroPace expects minimal impact of tariffs on its operations and financial results - MSN
Neuropace Provides Update On Tariff Status - marketscreener.com
NeuroPace Reports 'Minimal impact' From Trump Tariffs - marketscreener.com
NeuroPace Expects Minimal Impact from Trade Tariffs - TipRanks
NeuroPace expects minimal tariff impact, maintains guidance - Investing.com Australia
NeuroPace Provides Update on Tariff Status - The Manila Times
US Manufacturing Shield: NeuroPace Dodges Tariff Headwinds as Peers Struggle - Stock Titan
NeuroPace stock target cut to $17 by Cantor Fitzgerald - Investing.com Australia
Contrasting DIH Holding US (NASDAQ:DHAI) & NeuroPace (NASDAQ:NPCE) - Defense World
What is Leerink Partnrs' Forecast for NeuroPace Q1 Earnings? - MarketBeat
Cantor Fitzgerald cuts NeuroPace stock target to $17 By Investing.com - Investing.com Canada
Cantor Fitzgerald cuts NeuroPace stock target to $17 - Investing.com
NeuroPace reports 82% seizure reduction in epilepsy study By Investing.com - Investing.com Australia
NeuroPace Reports Data From 3-year Post-Approval Study Of RNS System In Focal Epilepsy - Nasdaq
NeuroPace reports 82% seizure reduction in epilepsy study - Investing.com
NeuroPace announces data from long-term post-approval study of RNS System - TipRanks
NeuroPace Announces Data From a Long-Term Post-Approval - GlobeNewswire
Neuropace Inc (NPCE) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
0.94%
大文字化:
|
ボリューム (24 時間):